Friday December 15th 2017

[Articles] Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension…

Adverse events and immunogenicity were not increased in the second year of continuous treatment with daclizumab HYP or during treatment washout and re-initiation. These results support further assessment of daclizumab HYP for relapsing-remitting multiple sclerosis. (Source: Lancet Neurology)

Follow this link: 

[Articles] Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension…

Leave a Comment

More from category

Germany’s Merck to make new bid to enter U.S. MS pill market
Germany’s Merck to make new bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the [Read More]

Researchers develop new method for quickly detecting signs of multiple sclerosis
Researchers develop new method for quickly detecting signs of multiple sclerosis

A METHOD for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research [Read More]

Terror survivors have increased risk of frequent migraine, tension headaches
Terror survivors have increased risk of frequent migraine, tension headaches

Survivors of a terror attack have an increased risk of frequent migraine and tension headaches after the attack, [Read More]

Scientists discover blood sample detection method for multiple sclerosis
Scientists discover blood sample detection method for multiple sclerosis

(University of Huddersfield) Researchers identified two natural biomarker compounds present in the blood. (Source: [Read More]

Study: The medical community isn’t prepared for the looming pandemic of neurodegenerative diseases like Parkinson’s
Study: The medical community isn’t prepared for the looming pandemic of neurodegenerative diseases like Parkinson’s

(Natural News) Parkinson’s disease is the second most common neurodegenerative disease plaguing people today, with an [Read More]